Published in Lab Business Week, April 17th, 2005
Research and development expenses for the second quarter of FY2005 totaled $1.6 million as compared to $.7 million for the second quarter of FY2004. The increase in R&D expenses reflects an expansion in the company's Onconase phase IIIb clinical trial for malignant mesothelioma, primarily in Europe, Australia and New Zealand.
The company also incurred higher data management and clinical trial monitoring fees related to the phase IIIb trial as well as expenses...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.